» Articles » PMID: 10330256

Mechanisms of Desensitization to a PDE Inhibitor (milrinone) in Conscious Dogs with Heart Failure

Overview
Journal Am J Physiol
Specialty Physiology
Date 1999 May 18
PMID 10330256
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The goal of this study was to determine the extent to which the effects of milrinone were desensitized in heart failure (HF) and to determine the mechanisms, i.e., whether these effects could be ascribed to changes in cAMP or phosphodiesterase (PDE) activity in HF. Accordingly, we examined the effects of milrinone in seven conscious dogs before and after HF was induced by rapid ventricular pacing at 240 beats/min. The dogs were chronically instrumented for measurements of left ventricular (LV) pressure and first derivative of LV pressure (dP/dt), arterial pressure, LV internal diameter, and wall thickness. Milrinone (10 micrograms . kg-1. min-1 iv) increased LV dP/dt by 1,854 +/- 157 from 2,701 +/- 105 mmHg/s (P < 0.05) before HF. After HF the increase in LV dP/dt in response to milrinone was attenuated significantly (P < 0.05); it increased by 615 +/- 67 from 1,550 +/- 107 mmHg/s, indicating marked desensitization. In the presence of ganglionic blockade the increases in LV dP/dt (+445 +/- 65 mmHg/s) in response to milrinone were markedly less (P < 0.01), and milrinone increased LV dP/dt even less in HF (+240 +/- 65 mmHg/s). cAMP and PDE activity were measured in endocardial and epicardial layers in normal and failing myocardium. cAMP was decreased significantly (P < 0.05) in LV endocardium (-26%) but not significantly in LV epicardium (-14%). PDE activity was also decreased significantly (P < 0.05) in LV endocardium (-18%) but not in LV epicardium (-4%). Thus significant desensitization to milrinone was observed in conscious dogs with HF. The major effect was autonomically mediated. The biochemical mechanism appears to be due in part to the modest reductions in PDE activity in failing myocardium, which, in turn, may be a compensatory mechanism to maintain cAMP levels in HF. Reductions in cAMP and PDE levels were restricted to the subendocardium, suggesting that the increased wall stress and reduced coronary reserve play a role in mediating these changes.

Citing Articles

An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases.

Chen S, Yan C Expert Opin Drug Discov. 2020; 16(2):183-196.

PMID: 32957823 PMC: 7854486. DOI: 10.1080/17460441.2020.1821643.


Oscillation of cAMP and Ca(2+) in cardiac myocytes: a systems biology approach.

Kamide T, Okumura S, Ghosh S, Shinoda Y, Mototani Y, Ohnuki Y J Physiol Sci. 2015; 65(2):195-200.

PMID: 25585963 PMC: 10717207. DOI: 10.1007/s12576-014-0354-3.


Cyclic AMP synthesis and hydrolysis in the normal and failing heart.

Guellich A, Mehel H, Fischmeister R Pflugers Arch. 2014; 466(6):1163-75.

PMID: 24756197 DOI: 10.1007/s00424-014-1515-1.


Conserved expression and functions of PDE4 in rodent and human heart.

Richter W, Xie M, Scheitrum C, Krall J, Movsesian M, Conti M Basic Res Cardiol. 2010; 106(2):249-62.

PMID: 21161247 PMC: 3032896. DOI: 10.1007/s00395-010-0138-8.


Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals.

Abi-Gerges A, Richter W, Lefebvre F, Mateo P, Varin A, Heymes C Circ Res. 2009; 105(8):784-92.

PMID: 19745166 PMC: 2792993. DOI: 10.1161/CIRCRESAHA.109.197947.